Antimicrobial Activity of Different Antimicrobial Peptides (AMPs) Against Clinical Methicillin-resistant Staphylococcus aureus (MRSA).
Eleonora Ciandrini, Gianluca Morroni, Daniela Arzeni, Wojciech Kamysz, Damian Neubauer, Elzbieta Kamysz, Oscar Cirioni, Lucia Brescini, Wally Baffone, Raffaella Campana
Author Information
Eleonora Ciandrini: Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Gianluca Morroni: Infectious Disease Clinic, Department of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy.
Daniela Arzeni: Infectious Disease Clinic, Department of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy.
Wojciech Kamysz: Faculty of Pharmacy, Department of Inorganic Chemistry, Medical University of Gdansk, Gdansk, Poland.
Damian Neubauer: Faculty of Pharmacy, Department of Inorganic Chemistry, Medical University of Gdansk, Gdansk, Poland.
Elzbieta Kamysz: Faculty of Chemistry, Department of Molecular Biotechnology, University of Gdansk, Gdansk, Poland.
Oscar Cirioni: Infectious Disease Clinic, Department of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy.
Lucia Brescini: Infectious Disease Clinic, Department of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy.
Wally Baffone: Department of Biomolecular Sciences, Division of Toxicological, Hygiene and Environmental Sciences, University of Urbino Carlo Bo, Urbino, Italy.
Raffaella Campana: Department of Biomolecular Sciences, Division of Toxicological, Hygiene and Environmental Sciences, University of Urbino Carlo Bo, Urbino, Italy.
BACKGROUND: Antimicrobial research is being focused to look for more effective therapeutics against antibiotic-resistant infections caused by methicillin-resistant Staphylococcus aureus (MRSA). In this direction, antimicrobial peptides (AMP) appear as promising tool. OBJECTIVES: This study evaluated the antimicrobial activity of different AMPs (Citropin 1.1, Temporin A, Pexiganan, CA(1-7)M(2-9)NH2, Pal-KGK-NH2, Pal-KKKK-NH2, LL-37) against human MRSA clinical isolates. METHODS: The Minimum Inhibitory Concentration (MIC) was assessed for each AMP; then, the most active ones (Citropin 1.1, Temporin A, CA(1-7)M(2-9)NH2 and Pal-KGK-NH2) were tested against selected MRSA strains by time-kill studies. RESULTS: The lowest MIC value was observed for Pal-KGK-NH2 (1 µg/ml), followed by Temporin A (4- 16 µg/ml), CA(1-7)M(2-9)NH2 (8-16 µg/ml) and Citropin 1.1 (16-64 µg/ml), while higher MICs were evidenced for LL-37, Pexiganan and Pal-KKKK-NH2 (> 128 µg/ml). In time-kill experiments, Citropin 1.1 and CA(1-7)M(2-9)NH2 showed a relatively high percentage of growth inhibition (>30 %) for all the tested MRSA clinical isolates, with a dose-dependent activity resulting in the highest percentage of bacterial growth inhibition (89.39%) at 2MIC concentration. CONCLUSION: Overall, our data demonstrated the potential of some AMPs against MRSA isolates, such as Citropin 1.1 and CA(1-7)M(2-9)NH2, that represents a promising area of development for different clinical applications.
